Functional Genomics In Vivo Reveal Metabolic Dependencies of Pancreatic Cancer Cells.
cancer metabolism
in vivo CRISPR screen
pancreatic cancer
tumor immune evasion
Journal
Cell metabolism
ISSN: 1932-7420
Titre abrégé: Cell Metab
Pays: United States
ID NLM: 101233170
Informations de publication
Date de publication:
05 01 2021
05 01 2021
Historique:
received:
28
04
2020
revised:
12
08
2020
accepted:
19
10
2020
pubmed:
6
11
2020
medline:
30
11
2021
entrez:
5
11
2020
Statut:
ppublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) cells require substantial metabolic rewiring to overcome nutrient limitations and immune surveillance. However, the metabolic pathways necessary for pancreatic tumor growth in vivo are poorly understood. To address this, we performed metabolism-focused CRISPR screens in PDAC cells grown in culture or engrafted in immunocompetent mice. While most metabolic gene essentialities are unexpectedly similar under these conditions, a small fraction of metabolic genes are differentially required for tumor progression. Among these, loss of heme synthesis reduces tumor growth due to a limiting role of heme in vivo, an effect independent of tissue origin or immune system. Our screens also identify autophagy as a metabolic requirement for pancreatic tumor immune evasion. Mechanistically, autophagy protects cancer cells from CD8+ T cell killing through TNFα-induced cell death in vitro. Altogether, this resource provides metabolic dependencies arising from microenvironmental limitations and the immune system, nominating potential anti-cancer targets.
Identifiants
pubmed: 33152324
pii: S1550-4131(20)30550-7
doi: 10.1016/j.cmet.2020.10.017
pmc: PMC7790894
mid: NIHMS1644223
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
211-221.e6Subventions
Organisme : NCI NIH HHS
ID : DP2 CA228042
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests K.B. is scientific advisor to Nanocare Pharmaceuticals and a consultant to Barer Institute.